Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 2Rectal Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1

Interventions

Oxaliplatin 270Bevacizumab 260Fluorouracil 249Irinotecan 240Leucovorin 218Capecitabine 196Cetuximab 161Colonoscopy 74Folfox protocol 70Panitumumab 64regorafenib 62Drug Therapy 52Radiotherapy 50HMPL-013 50Blood Specimen Collection 45trifluridine tipiracil drug combination 43pembrolizumab 41Surveys and Questionnaires 35Standard of Care 35Nivolumab 34Neoadjuvant Therapy 34Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 31IFL protocol 27Trifluridine 26Interviews as Topic 26Celecoxib 26XELOX 25Early Intervention, Educational 24Specimen Handling 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Colorectal Neoplasms × CB-839 × Clear all
NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1/2 Completed
50 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

NCT03263429 2024-08-30

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Vanderbilt-Ingram Cancer Center

Phase 1/2 Completed
29 enrolled 17 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡